Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota

Citations Over TimeTop 1% of 2017 papers

Abstract

Alzheimer's disease is the most common form of dementia in the western world, however there is no cure available for this devastating neurodegenerative disorder. Despite clinical and experimental evidence implicating the intestinal microbiota in a number of brain disorders, its impact on Alzheimer's disease is not known. To this end we sequenced bacterial 16S rRNA from fecal samples of Aβ precursor protein (APP) transgenic mouse model and found a remarkable shift in the gut microbiota as compared to non-transgenic wild-type mice. Subsequently we generated germ-free APP transgenic mice and found a drastic reduction of cerebral Aβ amyloid pathology when compared to control mice with intestinal microbiota. Importantly, colonization of germ-free APP transgenic mice with microbiota from conventionally-raised APP transgenic mice increased cerebral Aβ pathology, while colonization with microbiota from wild-type mice was less effective in increasing cerebral Aβ levels. Our results indicate a microbial involvement in the development of Abeta amyloid pathology, and suggest that microbiota may contribute to the development of neurodegenerative diseases.

Related Papers

• → Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664(2006)232 cited
• → Aging Increased Amyloid Peptide and Caused Amyloid Plaques in Brain of Old APP/V717I Transgenic Mice by a Different Mechanism than Mutant Presenilin1(2000)103 cited
• → Modeling Alzheimer's disease in transgenic mice: effect of age and of Presenilin1 on amyloid biochemistry and pathology in APP/London mice(2000)74 cited
• → Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in β‐amyloid load(2005)50 cited
• → Proteolytical processing of mutated human amyloid precursor protein in transgenic mice(1997)36 cited